Icsm Regular Monitoring Tt Response

---
name: icsm-regular-monitoring-tt-response
description: Conducts regular monitoring for testosterone therapy response and adverse events. Triggered when testosterone therapy is initiated and the clinician plans follow‑up, asking when to check symptom improvement or what to monitor for side effects.
---

# Conduct regular monitoring for testosterone therapy response and adverse events

## STEP 1 — Gather Information
Collect baseline and follow‑up data: symptom assessment (libido, energy, mood, erectile function), adverse event review, total testosterone (tT), hematocrit, PSA, and perform digital rectal examination (DRE).

## STEP 2 — Rule In / Rule Out
Is there an abnormal finding (hematocrit ≥54%, PSA rise ≥0.4 ng/mL, worsening hypogonadal symptoms, or no symptom improvement)?  
- If **yes**, proceed to Step 3 to classify the abnormality.  
- If **no**, continue current testosterone therapy and schedule the next routine visit per monitoring schedule (3 mo, 6 mo, then yearly).

## STEP 3 — Classify or Stratify
Classify the abnormality:  
| Finding | Mild | Moderate | Severe |  
|---|---|---|---|  
| Hematocrit | 54‑55% | 56‑60% | >60% |  
| PSA change | 0.4‑1.0 ng/mL rise | >1.0 ng/mL rise or velocity >0.75 ng/mL/yr | Rapid rise or >2.0 ng/mL |  
| Symptom response | Partial improvement | No improvement | Worsening |  
Based on the highest severity level, assign a grade.

## STEP 4 — Decide
Action based on classification:  
- **Mild**: Repeat labs in 4‑6 weeks, consider lifestyle measures, continue same dose.  
- **Moderate**: Reduce testosterone dose or change formulation, repeat labs in 4‑6 weeks, evaluate adherence.  
- **Severe**: Hold testosterone therapy, investigate cause (e.g., polycythemia, prostate pathology), and consider specialist referral before restarting.

## Clinical Guardrails / Mimics / Pitfalls
Do not ignore a rising hematocrit ≥54% as it increases thrombotic risk; do not delay PSA evaluation in men with baseline PSA >1.0 ng/mL or family history of prostate cancer; avoid continuing therapy if symptoms worsen without investigating non‑hormonal causes.

## Concrete Clinical Example
A 58‑year‑old man starts testosterone gel 5 mg/day. At 3‑month visit, hematocrit is 56% (moderate), PSA unchanged, libido improved. Decision: reduce gel to 2.5 mg/day, recheck hematocrit in 6 weeks; if normal, maintain reduced dose.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036